{"protocolSection": {"identificationModule": {"nctId": "NCT00739674", "orgStudyIdInfo": {"id": "0954A-335"}, "secondaryIdInfos": [{"id": "2008_022"}, {"id": "MK0954A-335"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)", "officialTitle": "Randomized Open-label Trial to Evaluate the Effectiveness of Diet Management With a Losartan Titration Regimen Versus Losartan Titration Regimen Alone on Blood Pressure Reduction in Hypertensives."}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-07-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-01-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-08-20", "studyFirstSubmitQcDate": "2008-08-21", "studyFirstPostDateStruct": {"date": "2008-08-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-07-14", "resultsFirstSubmitQcDate": "2010-07-14", "resultsFirstPostDateStruct": {"date": "2010-08-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To evaluate the effectiveness of diet management with a losartan based titration regimen versus losartan based titration regimen alone on blood pressure reduction in hypertensive patients."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 992, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Losartan-Based Regimen Alone (L Group)", "type": "ACTIVE_COMPARATOR", "description": "Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.", "interventionNames": ["Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])"]}, {"label": "Diet Management and Losartan-Based Regimen (DML Group)", "type": "EXPERIMENTAL", "description": "Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.", "interventionNames": ["Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])", "Behavioral: Low Salt Diet"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])", "description": "Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:\n\nPatients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:\n\n* Losartan 50 mg\n* Losartan 100 mg\n* Losartan 100 mg/HCTZ 12.5 mg\n* Losartan 100 mg/HCTZ 25 mg\n* Losartan 100 mg/HCTZ 25 mg + CCB\n\nPatients with severe hypertension:\n\n* Losartan 50 mg/HCTZ 12.5 mg\n* Losartan 100 mg/HCTZ 12.5 mg\n* Losartan 100 mg/HCTZ 25 mg\n* Losartan 100 mg/HCTZ 25 mg + CCB\n* Losartan 100 mg/HCTZ 25 mg + increasing CCB", "armGroupLabels": ["Diet Management and Losartan-Based Regimen (DML Group)", "Losartan-Based Regimen Alone (L Group)"]}, {"type": "BEHAVIORAL", "name": "Low Salt Diet", "description": "Low-salt intake diet (Dietary Approaches to Stop Hypertension \\[DASH\\]) including:\n\n* Healthy diet\n* Reduction in sodium intake to less than 2300 mmol/day\n* Low alcohol consumption (less than 2 standard drinks/day)", "armGroupLabels": ["Diet Management and Losartan-Based Regimen (DML Group)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 14 weeks of treatment", "timeFrame": "14 Weeks"}, {"measure": "Change in Systolic Blood Pressure From Baseline to Week 14", "timeFrame": "14 Weeks"}, {"measure": "Change in Diastolic Blood Pressure From Baseline to Week 14", "timeFrame": "14 Weeks"}], "secondaryOutcomes": [{"measure": "Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 6 weeks of treatment", "timeFrame": "6 Weeks"}, {"measure": "Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 10 weeks of treatment", "timeFrame": "10 Weeks"}, {"measure": "Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 40 weeks of treatment", "timeFrame": "40 Weeks"}, {"measure": "Change in Systolic Blood Pressure From Baseline to Week 6", "timeFrame": "6 Weeks"}, {"measure": "Change in Diastolic Blood Pressure From Baseline to Week 6", "timeFrame": "6 Weeks"}, {"measure": "Change in Systolic Blood Pressure From Baseline to Week 10", "timeFrame": "10 Weeks"}, {"measure": "Change in Diastolic Blood Pressure From Baseline to Week 10", "timeFrame": "10 Weeks"}, {"measure": "Time to Achieve the Target Blood Pressure From Baseline", "description": "Time to achieve the target blood pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics).", "timeFrame": "14 Weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Non Diabetic, Newly Diagnosed And Untreated For Mild To Moderate Hypertension (blood pressure \\> 161; \\< 221; 140/90 mm Hg But \\< 180/110 mm Hg)\n* Non diabetic, newly diagnosed and untreated for severe hypertension (blood pressure \\> 180/110 mm Hg but \\< 200/120 mm Hg); Patients who are asymptomatic with no evidence of significant end organ damage including direct pressure effects can be included. Patients in an urgency/emergency state are to be excluded\n* Or Diabetic, Newly Diagnosed With Hypertension And Untreated With Mild To Moderate Hypertension (blood pressure \\> 161;\\< 221; 130/80 mm Hg But \\< 160/100 mm Hg); Or Patient Receiving One Antihypertensive Agent (Monotherapy Only) Used To Treat Hypertension For At Least 4 Weeks And Whose Blood Pressure Is Not Controlled: blood pressure \\> 161;\\< 221; 140/90 mm Hg But \\< 160/100 mm Hg Or For Diabetic And/Or Coronary Artery Disease Patients: blood pressure \\> 161;\\< 221; 130/80 mm Hg But \\> 161;\\< 221; 150/90 mm Hg\n* The Antihypertensive Agent Will Need To Be Discontinued Prior To Starting Study Drug\n\nExclusion Criteria:\n\n* Known Secondary Hypertension Of Any Aetiology (E.G., Uncorrected Renal Artery Stenosis, Malignant Hypertension, Hypertensive Encephalopathy. Patient With Symptomatic Heart Failure (Classes 3 And 4). Patient With A Prior Myocardial Infarction Or Stroke Within The Last 6 Months\n* Patient Has Undergone Percutaneous Coronary Angioplasty, Has Had Coronary Artery Bypass Within The Last 6 Months Or Has Unstable Angina\n* Patient With Anuria Or Confirmed Clinically Significant Renal Or Hepatic Dysfunction (Taken From Current/Past Medical Records) And/Or Electrolyte Imbalance Laboratory Test Within The Last 3 Months Prior To Visit 1: Serum Creatinine \\> 130 \u00ccmol/L Or Creatinine Clearance \\< 45 Ml/Min, Ast \\> 3 Times Above The Normal Range, Alt \\> 3 Times Above The Normal Range, Serum Potassium \\< 3.5 Or \\> 5.5 Meq/L\n* Significant Liver Or Respiratory Disease, Cancer Or Other concomitant Disease That Is Likely To Affect Life Expectancy Of The Patient", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "First patient in: FEB-05-2008\n\nLast patient out: JAN-15-2010\n\nTotal number of sites: 109 sites in Canada", "groups": [{"id": "FG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including hydrochlorothiazide (HCTZ) 12.5 mg or 25 mg and calcium channel blocker (CCB) as needed to achieve target blood pressure."}, {"id": "FG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt Dietary Approaches to Stop Hypertension (DASH) diet management."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "535"}, {"groupId": "FG001", "numSubjects": "457"}]}, {"type": "Screening Failures", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "comment": "ITT population took at least one dose of the study medication and had one follow-up visit.", "numSubjects": "17"}]}, {"type": "Site 212 Removal", "achievements": [{"groupId": "FG000", "comment": "lack of source documentation \\& frequent discrepancies between source notes and case report entries.", "numSubjects": "19"}, {"groupId": "FG001", "comment": "lack of source documentation \\& frequent discrepancies between source notes and case report entries.", "numSubjects": "13"}]}, {"type": "No Follow-up Data", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Dietician Consultation >30 Days", "achievements": [{"groupId": "FG000", "comment": "Patients with dietician consultations \\>30 days after visit 1 were not included in the data analysis.", "numSubjects": "1"}, {"groupId": "FG001", "comment": "Patients with dietician consultations \\>30 days after visit 1 were not included in the data analysis.", "numSubjects": "9"}]}, {"type": "Intent-to-treat (ITT) Population", "achievements": [{"groupId": "FG000", "comment": "ITT population took at least one dose of the study medication and had one follow-up visit.", "numSubjects": "463"}, {"groupId": "FG001", "comment": "ITT population took at least one dose of the study medication and had one follow-up visit.", "numSubjects": "400"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "354"}, {"groupId": "FG001", "numSubjects": "335"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "181"}, {"groupId": "FG001", "numSubjects": "122"}]}], "dropWithdraws": [{"type": "Screening failures", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "Site 212 removal", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "No follow-up data", "reasons": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Dietician consultation >30 days", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "52"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Reason missing", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Clinic closed", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Patient moved", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Non compliant", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Unable to attend visit", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Home monitoring off meds", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Erectile dysfunction", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.\n\nThe Baseline Measures are reported for the Intent-to-treat (ITT) population (i.e. took at least one dose of the study medication and returned for one follow-up visit)."}, {"id": "BG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.\n\nThe Baseline Measures are reported for the Intent-to-treat (ITT) population (i.e. took at least one dose of the study medication and returned for one follow-up visit)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "463"}, {"groupId": "BG001", "value": "400"}, {"groupId": "BG002", "value": "863"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.05", "spread": "11.54"}, {"groupId": "BG001", "value": "54.59", "spread": "11.98"}, {"groupId": "BG002", "value": "55.38", "spread": "11.76"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "239"}, {"groupId": "BG001", "value": "208"}, {"groupId": "BG002", "value": "447"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "224"}, {"groupId": "BG001", "value": "192"}, {"groupId": "BG002", "value": "416"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "404"}, {"groupId": "BG001", "value": "369"}, {"groupId": "BG002", "value": "773"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "13"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "58"}]}]}, {"title": "Native Indian", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Cardiovascular Risk", "description": "Cardiovascular Risk according to Framingham Equation", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "High", "categories": [{"measurements": [{"groupId": "BG000", "value": "112"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "204"}]}]}, {"title": "Medium", "categories": [{"measurements": [{"groupId": "BG000", "value": "94"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "155"}]}]}, {"title": "Low", "categories": [{"measurements": [{"groupId": "BG000", "value": "218"}, {"groupId": "BG001", "value": "216"}, {"groupId": "BG002", "value": "434"}]}]}, {"title": "Not Available", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "62"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Diastolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.67", "spread": "9.19"}, {"groupId": "BG001", "value": "91.43", "spread": "9.98"}, {"groupId": "BG002", "value": "91.02", "spread": "9.57"}]}]}]}, {"title": "Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "151.23", "spread": "10.80"}, {"groupId": "BG001", "value": "151.11", "spread": "12.55"}, {"groupId": "BG002", "value": "151.17", "spread": "11.64"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "85.41", "spread": "19.95"}, {"groupId": "BG001", "value": "89.17", "spread": "20.18"}, {"groupId": "BG002", "value": "87.16", "spread": "20.13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 14 weeks of treatment", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "14 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "392"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "276"}, {"groupId": "OG001", "value": "270"}]}]}, {"title": "Did not Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.118", "statisticalMethod": "Fisher Exact", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving Target Blood Pressure at Week 6 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 6 weeks of treatment", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "6 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "431"}, {"groupId": "OG001", "value": "383"}]}], "classes": [{"title": "Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "231"}]}]}, {"title": "Did not Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "152"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.092", "statisticalMethod": "Fisher Exact", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving Target Blood Pressure at Week 10 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 10 weeks of treatment", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "10 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "399"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"title": "Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "257"}, {"groupId": "OG001", "value": "254"}]}]}, {"title": "Did not Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "116"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.122", "statisticalMethod": "Fisher Exact", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving Target Blood Pressure at Week 40 From Baseline", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) from baseline after 40 weeks of treatment", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 351 and 331 patients at week 40 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "40 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "351"}, {"groupId": "OG001", "value": "331"}]}], "classes": [{"title": "Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "264"}, {"groupId": "OG001", "value": "240"}]}]}, {"title": "Did not Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "91"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.434", "statisticalMethod": "Fisher Exact", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Change in Systolic Blood Pressure From Baseline to Week 14", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "14 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "392"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.01", "spread": "14.11"}, {"groupId": "OG001", "value": "-22.74", "spread": "15.81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.507", "statisticalMethod": "Regression, Linear", "statisticalComment": "Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Change in Diastolic Blood Pressure From Baseline to Week 14", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 357 patients at week 14 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "14 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "392"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.19", "spread": "9.33"}, {"groupId": "OG001", "value": "-12.05", "spread": "9.50"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.058", "statisticalMethod": "Regression, Linear", "statisticalComment": "Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Systolic Blood Pressure From Baseline to Week 6", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "6 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "431"}, {"groupId": "OG001", "value": "383"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.81", "spread": "14.92"}, {"groupId": "OG001", "value": "-18.85", "spread": "16.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.158", "statisticalMethod": "Regression, Linear", "statisticalComment": "Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Diastolic Blood Pressure From Baseline to Week 6", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 431 and 383 patients at week 6 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "6 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "431"}, {"groupId": "OG001", "value": "383"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.34", "spread": "9.29"}, {"groupId": "OG001", "value": "-9.76", "spread": "9.82"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.064", "statisticalMethod": "Regression, Linear", "statisticalComment": "Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Systolic Blood Pressure From Baseline to Week 10", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "10 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "399"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.11", "spread": "14.87"}, {"groupId": "OG001", "value": "-20.95", "spread": "16.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.262", "statisticalMethod": "Regression, Linear", "statisticalComment": "Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Diastolic Blood Pressure From Baseline to Week 10", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 399 and 370 patients at week 10 for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "10 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "399"}, {"groupId": "OG001", "value": "370"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.48", "spread": "8.80"}, {"groupId": "OG001", "value": "-11.42", "spread": "9.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.026", "statisticalMethod": "Regression, Linear", "statisticalComment": "Adjusted for study medication, age, gender, race, cardiovascular risk, baseline weight, and baseline waist circumference.", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Time to Achieve the Target Blood Pressure From Baseline", "description": "Time to achieve the target blood pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics).", "populationDescription": "463 and 400 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 437 and 386 patients for L group and DML group respectively.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Weeks", "timeFrame": "14 Weeks", "groups": [{"id": "OG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure."}, {"id": "OG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "437"}, {"groupId": "OG001", "value": "386"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.43", "lowerLimit": "6.24", "upperLimit": "8.62"}, {"groupId": "OG001", "value": "6.57", "lowerLimit": "6.29", "upperLimit": "6.85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.212", "statisticalMethod": "Log Rank", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "A total of 8 patients were removed from the safety population because they did not receive at least one dose of the study medication. Therefore, the safety population was based on 984 patients (531 in the L Group and 453 in the DML Group) of the total 992 enrolled patients.", "eventGroups": [{"id": "EG000", "title": "Losartan-Based Regimen Alone (L Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure.", "seriousNumAffected": 13, "seriousNumAtRisk": 531, "otherNumAffected": 55, "otherNumAtRisk": 531}, {"id": "EG001", "title": "Diet Management and Losartan-Based Regimen (DML Group)", "description": "Losartan-based regimen (50 mg or 100 mg once daily for 40 weeks) with sequential titration including HCTZ 12.5 mg or 25 mg and CCB as needed to achieve target blood pressure combined with low-salt DASH diet management.", "seriousNumAffected": 10, "seriousNumAtRisk": 453, "otherNumAffected": 46, "otherNumAtRisk": 453}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Pseudocyst", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Amyloidosis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Red blood cell sedimentation rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Metastases to bladder", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Multiple myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Prostate cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Epididymitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}], "otherEvents": [{"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Eye irritation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Abdominal mass", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Anal fissure", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 453}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Drug ineffective", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Helicobacter gastritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Nail infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 453}]}, {"term": "Drug exposure during pregnancy", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Incorrect dose administered", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Wrong technique in drug usage process", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Blood pressure decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "C-reactive protein abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Creatinine urine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Urea urine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Urine output decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Urine sodium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "White blood cell count abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Fluid retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Impaired fasting glucose", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 453}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 453}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Adjustment disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Personality disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Stress", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Microalbuminuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Renal cyst", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 453}]}, {"term": "Erectile dysfunction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 453}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Rash maculo-papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Endometrial ablation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 453}]}, {"term": "Labile blood pressure", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 531}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Canada", "Mexico"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000002118", "term": "Calcium"}], "ancestors": [{"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}], "browseLeaves": [{"id": "M5381", "name": "Calcium", "asFound": "Double-blind", "relevance": "HIGH"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M3777", "name": "Ethanol", "relevance": "LOW"}, {"id": "M21701", "name": "Losartan", "asFound": "Gradual", "relevance": "HIGH"}, {"id": "M5384", "name": "Calcium Channel Blockers", "asFound": "Length of stay", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}